Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Presentation Icons

Additional registration fee required

Faculty have requested this content not be shared outside of the session

CME Credit Offered

Abstract Award

Recording available 2/16-5/2

AIUM Credit

Foundation Awardee

Poster Icons

Abstract Award

Foundation Awardee

Poster Session 1

Category: Hypertension

Poster Session 1

(137) Discharge on Nifedipine Associated with Lower Self-Reported Systolic Blood Pressure Two Weeks Postpartum

Wednesday, February 11, 2026

10:30 AM - 12:00 PM

Submitting Author and Presenting Author(s)

Audra C. Fain, MD (she/her/hers)

Resident Physician
Department of Obstetrics and Gynecology, David Geffen School of Medicine at University of California, Los Angeles (UCLA)
Los Angeles, California, United States

Coauthor(s)

Jenny Y. Mei, MD (she/her/hers)

Clinical Assistant Professor
Stanford University
Stanford University, California, United States
MD

Maral Demirjian, MPH

Statistician
Department of Urology, David Geffen School of Medicine at University of California, Los Angeles (UCLA)
Los Angeles, California, United States
LK

Lorna Kwan, BS, MPH

Principal Statistician
Department of Urology, David Geffen School of Medicine at University of California, Los Angeles (UCLA)
Los Angeles, California, United States
Rashmi Rao, MD (she/her/hers)

Associate Clinical Professor
Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, David Geffen School of Medicine at University of California, Los Angeles (UCLA)
Los Angeles, California, United States
Thalia Mok, MD

Assistant Professor
David Geffen School of Medicine at University of California, Los Angeles (UCLA)
Los Angeles, California, United States

Objective:
Enhanced postpartum (PP) blood pressure (BP) control after hypertensive disorders of pregnancy (HDP) may lower long-term cardiovascular risk, but the most effective antihypertensive remains unclear. We compared self-reported PP BP among patients with HDP or chronic hypertension (CHTN) by antihypertensive medication.

Study Design:
Retrospective cohort study of patients with HDP or CHTN delivered at a quaternary care center between 2022 to 2025 and enrolled in a remote BP monitoring program upon discharge. Patients were included if discharged on either nifedipine or labetalol and logged at least one BP value. Those discharged on two or more medications were excluded. Primary outcome was mean self-reported systolic BP, diastolic BP, and mean arterial pressure (MAP) over the first 14 days PP. Secondary outcomes included self-reported 6-week PP systolic and diastolic BP. Primary and secondary outcomes were compared by antihypertensive agent with Chi-Square or Fisher’s exact and Wilcoxon rank-sum tests.

Results:
785 pregnancies with HDP or CHTN delivered and were discharged on a single antihypertensive agent: 650 on nifedipine, 135 on labetalol. The labetalol cohort was more likely to be obese, multiparous, and have CHTN (Table 1, p < 0.05). Self-reported systolic BP over the first 14 days PP were significantly lower in the nifedipine cohort (123.8 ± 7.2 vs. 126.8 ± 9.5, p = 0.003). There was no difference in self-reported diastolic BP or MAP over the first 14 days PP, or in self-reported 6-week BP values between groups (Table 2, p > 0.05).

Conclusion:
Discharge on nifedipine was associated with a modest but statistically significant reduction in self-reported systolic BP the first two weeks PP compared to labetalol. However, there were no significant differences in other BP measurements by antihypertensive agent, suggesting comparable overall PP BP control. Further studies are needed to determine if reduction of systolic BP in the immediate PP period reduces long-term cardiovascular risks. Current findings support individualized antihypertensive selection based on patient-specific factors.